Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine

Halofantrine (Hf) is a poorly water-soluble drug for treating malaria in endemic areas like tropical Africa, where caffeine-containing products are habitually consumed. Previous reports showed that caffeine increased the aqueous solubility of Hf at room temperature over 3 days. The aim of this study was to determine the effect of caffeine and caffeinecontaining beverages on dissolution and solubility of Hf and to investigate any possible interactions. The aqueous solubility and dissolution of Hf alone and in the presence of caffeine was investigated at pH 1.3, 5.9 and 7.4 using standard methods. The solubility of Hf in the presence of aqueous extracts of cocoa, coffee, black tea and green tea at pH 5.9 was also investigated. In 1 hour, caffeine markedly increased the aqueous solubility of Hf at pH 1.3, 5.9 and 7.4. Caffeine and caffeine-containing beverages markedly increased the aqueous solubility of Hf by between 100- to more than 1600- fold, with a 1672-fold increase by caffeine (from 76.6 ±7.8 ng/mL to128.2 ± 4.5 mg/mL) at pH 5.9. The dissolution of Hf tablets at pH 1.3, 5.9 and 7.4 showed the respective amounts released as 3.57 ± 0.09, 0.95 ± 0.19 and 0.260 ± 0.043 mg, but introduction of caffeine increased these values to 9.51 ± 0.23, 3.70 ± 0.12 and 0.52 ± 0.10 mg respectively, representing 3-fold, 4-fold and 2-fold respectively. These results prove physico-chemical interaction between caffeine and halofantrine. The consequence of this finding is unknown but may affect malaria chemotherapy when Hf is administered concurrently with caffeine-containing products.

[1]  C. Lambros,et al.  Comparison of in vitro and in vivo antimalarial activities of 9-phenanthrenecarbinols. , 2016, Annals of tropical medicine and parasitology.

[2]  G. Scriba,et al.  Analysis of the antimalarial drug halofantrine and its major metabolite N-desbutylhalofantrine in human plasma by high performance liquid chromatography. , 2006, Journal of pharmaceutical and biomedical analysis.

[3]  C. Onyeji,et al.  Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. , 2004, British journal of clinical pharmacology.

[4]  A. Adegoke,et al.  Determination of physicochemical properties of halofantrine. , 2003, African journal of medicine and medical sciences.

[5]  L. Lim,et al.  Caffeine and nicotinamide enhances the aqueous solubility of the antimalarial agent halofantrine. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  C. Onyeji,et al.  Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  M. Bras,et al.  Prolonged QT interval with halofantrine , 1993, The Lancet.

[8]  H. Webster,et al.  Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria , 1993, The Lancet.

[9]  K. Goa,et al.  Halofantrine , 2012, Drugs.

[10]  A. A. Rasool,et al.  Solubility enhancement of some water-insoluble drugs in the presence of nicotinamide and related compounds. , 1991, Journal of pharmaceutical sciences.

[11]  A. Breckenridge,et al.  Pharmacokinetics of halofantrine in man: effects of food and dose size. , 1989, British journal of clinical pharmacology.

[12]  D. Kariuki,et al.  EFFICACY OF MULTIPLE-DOSE HALOFANTRINE IN TREATMENT OF CHLOROQUINE-RESISTANT FALCIPARUM MALARIA IN CHILDREN IN KENYA , 1988, The Lancet.

[13]  T. Cosgriff,et al.  Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171,669). , 1982, The American journal of tropical medicine and hygiene.

[14]  L. H. Schmidt,et al.  Antimalarial Activities of Various 9-Phenanthrenemethanols with Special Attention to WR-122,455 and WR-171,669 , 1978, Antimicrobial Agents and Chemotherapy.

[15]  G. Scriba,et al.  Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine , 2007, European Journal of Clinical Pharmacology.

[16]  H. Webster,et al.  Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand. , 1988, Bulletin of the World Health Organization.

[17]  M. Tute,et al.  Rationalization of drug complexation in aqueous solution by use of Hückel frontier molecular orbitals. , 1980, Journal of pharmaceutical sciences.

[18]  J. Lange,et al.  Antimalarial arylaminopropanols. , 1972, Journal of Medicinal Chemistry.